After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, ...

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline. See why a Strong Buy rating is justified ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Viatris said on Friday that its experimental eye ointment failed to clear buildup or debris in the eyes in a late-stage study in patients with an inflammatory eye condition.

That's why it was notable when Viatris (VTRS-1.44%) announced a 9.1% increase in its quarterly dividend from $0.11 to $0.12 per share earlier this month. But can the stock afford the dividend hike?

Shares of Viatris Inc. VTRS rallied 3.82% to $9.24 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and ...

This was the stock's second consecutive day of losses.